BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
34 hedge funds and large institutions have $560K invested in BRAINSTORM CELL THERAPUTC in 2024 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 17 closing their positions.
6.17% more ownership
Funds ownership: 0.92% → 7.09% (+6.2%)
11% less funds holding
Funds holding: 38 → 34 (-4)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
55% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 11
78% less capital invested
Capital invested by funds: $2.52M → $560K (-$1.96M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSC
Caldwell Sutter Capital
Sausalito,
California
|
+$290K |
| 2 |
HF
HRT Financial
New York
|
+$37K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$18.4K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.9K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$11.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.59M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$41.1K |
| 3 |
AHB
Abner Herrman & Brock
Jersey City,
New Jersey
|
-$34K |
| 4 |
State Street
Boston,
Massachusetts
|
-$27K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$25.9K |
BCLI Hedge Fund Activity: Q4 2024 in Review
34 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q4 2024, worth a combined $560K — down 78% from $2.52M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of BCLI and 14 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 5 added.
The largest buyer was Caldwell Sutter Capital, opening a new position worth an estimated $290K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.59M sold.
- 34 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q4 2024, down from 38 in Q3 2024.
- Funds reported $560K of BRAINSTORM CELL THERAPUTC stock for Q4 2024, down 78% quarter-over-quarter.
- 14 funds opened new BRAINSTORM CELL THERAPUTC positions in Q4 2024 and 17 closed out, a net change of -3 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q4 2024 was Caldwell Sutter Capital, an estimated $290K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q4 2024 was Armistice Capital, an estimated $1.59M sold.
Based on aggregated 13F filings for Q4 2024.